Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
12.07.2026 13:43
Gilead's expansion beyond HIV therapies will surprise many investors.
2 Recession-Resistant Dividend Stocks to Buy and Hold
10.07.2026 16:20
You don't need to predict a recession to prepare your portfolio. These two stocks can help.
Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access
09.07.2026 07:12
Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative
09.07.2026 06:11
Gilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...
BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients
07.07.2026 14:00
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. BBG Advanced Therapies labs and offices BBG Advanced Therapies, a subsidiary
Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer
07.07.2026 13:00
– Seasoned executive brings extensive leadership experience spanning corporate development, business development and pipeline strategy – – Track record includes helping build and advance leading oncology franchises at Seagen, CytomX, Gilead and Merus – CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the appointment of Roland Gendron as Chief Business Offi
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
06.07.2026 18:36
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
06.07.2026 08:58
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155
06.07.2026 05:51
HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.
Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?
05.07.2026 12:59
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate […]
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
27.06.2026 04:15
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
27.06.2026 03:10
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
26.06.2026 14:45
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
26.06.2026 13:10
https://www.cdc.gov/ebola/situation-summary/index.html
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
25.06.2026 10:45
RAHWAY, N.J., June 25, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative br
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
23.06.2026 11:45
FOSTER CITY, Calif., June 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (ADC
3 S&P 500 Stocks with Exciting Potential
23.06.2026 09:52
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.
Gilead Sciences: The Market Is Underestimating Its Growth Runway
23.06.2026 09:00
Gilead stock looks like a long-term value buy after the pullback, with HIV growth, Yeztugo sales upside, and a safe dividend. Click to read more about GILD.
Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy To Treat Adult Patients With Unresectable Or Metastatic Triple-Negative Breast Cancer
23.06.2026 07:46
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients